Alzheimer; News from the web:

By the close of this year, the Indianapolis-based Fortune 500 pharmaceutical company Lilly , whose products have included the antidepressant Prozac and human insulin, will release the results of Expedition 3, a study testing a drug that targets amyloid in persons with mild stage dementia caused by Alzheimer’s disease. Its subjects are unique. They don’t simply have Alzheimer’s disease diagnosed by a careful history and exam. They have a brain scan showing amyloid accumulation.

Read all about it HERE